ALSUntangled no. 25: ursodiol. - Wikidata - awgldk - TriplyDB

ALSUntangled no. 25: ursodiol.

ALSUntangled no. 25: ursodiol.

http://www.wikidata.org/entity/Q38223869

about

ALSUntangled no. 25: ursodiol.

http://www.wikidata.org/entity/Q38223869

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

ALSUntangled no. 25: ursodiol.

@en

type

label

ALSUntangled no. 25: ursodiol.

@en

prefLabel

ALSUntangled no. 25: ursodiol.

@en

P1433

Q38223869-E4B8FA16-845F-45AB-AD97-4092BEC0EEA6

P1476

Q38223869-ACD29F24-CED5-45E3-A1E2-5C15BA3BC378

P2093

Q38223869-72D8822E-C096-4C33-8583-2CD27AFD8002

P2860

Q38223869-14DD0789-1A3E-4797-A329-9EA17A7EBEC7

Q38223869-183A4968-44DB-4B89-A598-4243EF2B2CCB

Q38223869-1D713B76-0DEA-4BBC-AD5A-AB48B705CAE7

Q38223869-2CAD3FA9-AA76-49BD-A41D-C0B51F3DF32E

Q38223869-41CE0181-630E-44F5-98E8-F9C977014D55

Q38223869-48E424B0-A24B-4E03-AA0F-84D626979455

Q38223869-63213CDD-D9A2-44ED-B034-64CE121A1499

Q38223869-7A625F31-CE14-470A-BE74-7BD480C9CBB6

Q38223869-852FBF37-3573-451F-B81C-5109F34757FA

Q38223869-885BA4C8-FEFC-4268-9F3C-32CAD4C3E9E7

P304

Q38223869-D65A6DA8-9164-4D26-9FFA-2D673CAB43F5

P31

Q38223869-693243FD-34C6-4834-8E42-6CE97295D295

P356

Q38223869-94BFA3F8-24C6-4A93-A258-65980E36C92F

P433

Q38223869-B0528848-C27E-4942-A997-A69C18A36AA7

P478

Q38223869-4D385531-9060-424B-9144-B9EF08E5C231

P577

Q38223869-522FA8F3-C69C-496D-AA0B-9C1F7AA770BC

P5875

Q38223869-B8FDA0E7-CE4A-476D-A4F3-7A92FF27F818

P698

Q38223869-13536BFC-D23D-454E-AE3E-679F72B12534

P356

21678421.2014.931010

P1433

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

P1476

ALSUntangled no. 25: ursodiol.

@en

P2093

ALSUntangled Group

http://www.w3.org/2001/XMLSchema#string

P2860

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants

Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation

Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis

Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway.

Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats

Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial

Ursodeoxycholic acid prevents apoptosis of mouse sensory neurons induced by cisplatin by reducing P53 accumulation.

P304

475-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/21678421.2014.931010

http://www.w3.org/2001/XMLSchema#string

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266614568

http://www.w3.org/2001/XMLSchema#string

P698

24972316

http://www.w3.org/2001/XMLSchema#string